Welcome to our dedicated page for Tenaya Therapeutics news (Ticker: TNYA), a resource for investors and traders seeking the latest updates and insights on Tenaya Therapeutics stock.
Tenaya Therapeutics, Inc. (TNYA) is a clinical-stage biotechnology company pioneering gene therapies and regenerative approaches for heart disease. This news hub provides investors and medical professionals with official updates on clinical developments, financial disclosures, and scientific advancements.
Access real-time updates on TNYA's investigational programs targeting genetic cardiomyopathies through AAV-based gene delivery and cellular regeneration technologies. Our curated feed includes earnings reports, FDA submissions, partnership announcements, and peer-reviewed research findings.
Key coverage areas span Phase 1/2 trial results for MYBPC3-associated hypertrophic cardiomyopathy therapies, manufacturing facility expansions, intellectual property milestones, and presentations at major cardiology conferences. Bookmark this page for verified updates on Tenaya's progress in developing potentially curative cardiac treatments.
Tenaya Therapeutics (NASDAQ: TNYA) reported its Q1 2024 financial results, revealing a net loss of $32.2 million, or $0.40 per share. The company raised $47 million in net proceeds, extending its cash runway to the second half of 2025. R&D expenses were $25.1 million, slightly down from $25.6 million in Q1 2023, while G&A expenses remained flat at $8.7 million.
Tenaya continues to focus on its gene therapy programs, expecting initial data from its TN-201 Phase 1b trial in H2 2024 and has activated clinical sites for its TN-401 Phase 1b trial. In line with cost containment measures, Tenaya plans to cut its workforce by 22%.
Recent academic publications highlight the potential of their TN-301 for heart failure and TN-401 for ARVC. With strategic hires and ongoing innovations, Tenaya aims to meet critical milestones in its clinical programs.
Tenaya Therapeutics, Inc. will showcase its advances in capsid engineering, gene editing, and manufacturing at the ASGCT 27th Annual Meeting. The company will present seven abstracts highlighting its capabilities in genetic medicines for heart disease. Tenaya's pipeline includes clinical-stage gene therapies for cardiomyopathies and research on gene therapy, gene editing, and cardiac cell regeneration using AAV as a delivery vehicle. The presentations will cover capsid engineering insights, gene editing efforts, and manufacturing process optimizations to improve AAV-based gene therapies' safety and efficacy.
